Decreased fragile histidine triad gene messenger RNA expression in lung cancer

Clinical Lung Cancer

Volumn 7, Issue 6, 2006, Pages 412-416

  Sasaki, Hidefumi ^a   Haneda, Hiroshi ^a   Yukiue, Haruhiro ^a   Kobayashi, Yoshihiro ^a   Yano, Motoki ^a   Fujii, Yoshitaka ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

Immunohistochemistry; LightCycler ; p21; Prognosis; Tumorigenesis

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; PROTEIN P21;

ADULT; AGE; AGED; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOG RANK TEST; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TISSUE DISTRIBUTION;

EID: 33745886797     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2006.n.026     Document Type: Article

References (32)

1. Ginsberg J, Kris K, Armstrong G. Cancer of the lung. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Principles and Practice of Oncology. 4th ed. Philadelphia, PA: Lippincott; 1993:673-682.
2. Yasuda K, Ayabe H, Ide H, et al. Thoracic and cardiovascular surgery in Japan during 1998. Annual report by the Japanese Association for Thoracic Surgery. Committees of Science. Jpn J Thorac Cardiovasc Surg 2000; 48:401-415.
3. Postmus PE. The experience of the lung cancer cooperative group of the European Organization for Research and Treatment of Cancer. Lung Cancer Cooperative Group of the EORTC. Chest Suppl 1997; 113:28S-31S.
4. Ohta M, Inoue H, Cotticelli G, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t (3:8) breakpoint, is abnormal indigestive tract cancers. Cell 1996; 84:587-597.
5. Sozzi G, Veronese L, Negrini M, et al. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 1996; 85:17-26.
6. Sozzi G, Tornielli S, Tagliabue E, et al. Absence of Fhit protein in primary lung tumor and cell lines with FHIT gene abnormalities. Cancer Res 1997; 57:5207-5212.
7. Tseng E, Kemp L, Khuri R, et al. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res 1999; 59:4798-4803.
8. Fong M, Biesterveld J, Virmani A, et al. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res 1997; 57:2256-2267.
9. Negrini M, Monaco C, Vorechovsky I, et al. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 1996; 56:3173-3179.
10. Ahmadian M, Wistuba II, Fong KM, et al. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res 1997; 57:3664-3668.
11. Sozzi G, Pastorino U, Moiraghi L, et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 1998; 58:5032-5037.
12. Tomizawa Y, Nakajima T, Kohno T, et al. Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma. Cancer Res 1998; 58:5478-5483.
13. Geradt J, Fong M, Zimmerman V, et al. Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features. Br J Cancer 2000; 82:1191-1197.
14. Campiglio M, Pekarsky Y, Menard S, et al. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res 1999; 59:3866-3869.
15. Zochbauer-Muller S, Wistuba I, Minna D, et al. Fragile histidine traid (FHIT) gene abnormalities in lung cancer. Clin Lung Cancer 2000; 2:141-145.
16. Wittwer T, Ririe M, Andrew V, et al. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques 1997; 22:176-181.
17. Japan Lung Cancer Society. General Rule for Clinical and Pathological Record of Lung Cancer. 5th ed. Tokyo, Japan: Kanehara Publishing; 1999?:5:1-177.
18. Siprashvili Z, Sozzi G, Barnes D, et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 1997; 94:13771-13776.
19. Sard L, Accornero P, Tornielli S, et al. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci USA 1999; 96:8489-8492.
20. El-Deiry S, Tokino T, Velculescu E, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-825.
21. Harper W, Adami R, Wei N, et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75:805-816.
22. Xiong Y, Hannon J, Zhang H, et al. p21 is a universal inhibitor of cyclin kinases. Nature (Lond) 1993; 366:701-704.
23. Akita K, Inagaki H, Sato S, et al. p185Her-2/neu and p21CIP/WAF1 expression in primary tumors and lymph node metastasis in non-small cell lung cancer. Jpn J Cancer Res 2002; 93:1007-1011.
24. Shoji T, Tanaka F, Takata T, et al. Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol 2002; 20:3865-3871.
25. Knudson G Jr. Retinoblastoma: a prototypic hereditary neoplasm. Semin Oncol 1978; 5:57-60.
26. Nelson H, Wiencke K, Gunn L, et al. Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tabacco carcinogens and asbestos. Cancer Res 1998; 58:1804-1807.
27. Mao L, Fan H, Lotan R, et al. Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines. Cancer Res 1996; 56:5128-5131.
28. Druck T, Kastury K, Hadaczek P, et al. Loss of heterozygosity at the familial RCC t (3:8) locus in most clear cell renal carcinomas. Cancer Res 1995; 55:5348-5353.
29. Virgilio L, Shuster M, Gollin M, et al. FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci U S A 1996; 93:9770-9775.
30. Merlo A, Herman G, Mao L, et al. 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/ CDKN2/MTS1in human cancers. Nat Med 1995; 1:686-692.
31. Baylin B, Herman G, Graff R, et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998; 72:141-196.
32. Zochbauer-Muller S, Fong M, Maitra A, et al. 5′CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung cancer. Cancer Res 2001; 61:3581-3585.